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was 14.10, 14.05 for LF, and 14.02 for PNF. Both LF and PNFwere dominated by CCH.
Sensitivity analysis confirmed the model was sensitive to changes in clinical effi-
cacy. Cost-effectiveness acceptability curves indicated that CCHwasmost likely to
be cost-effective across a wide range of willingness to pay, including values over
$100,000 per QALY gained. CONCLUSIONS: CCH was less expensive and was asso-
ciated with slightly more QALYs than LF and PNF for treatment of Dupuytren’s
contracture.
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OBJECTIVES: The cost of hip fractures associated with osteoporosis have become a
growing burden on the US health care system. Cost-effective treatments are
needed to prevent hip fractures in postmenopausal women with osteoporosis and
reduce the amount of resources consumed by these preventable events. The ob-
jective of this study was to develop a decision tree model to assess the cost-effec-
tiveness of four treatment options: alendronate, risedronate, ibandronate and a
“no treatment group” for the prevention of hip fractures. METHODS: A decision
tree model was developed from the third-party payer perspective using published
efficacy results from randomized controlled trials. Patients were assumed to have
osteoporosis, aged  65 years, be fully adherent and unable to change or discon-
tinue medication therapy. The incidence of hip fracture was estimated from the
literature. Medication costs were assigned from published wholesale acquisition
costs (WAC) by First DataBank. The mean cost of hip fractures and all direct costs
associated with 12-month post-fracture treatment were estimated from the liter-
ature. All costs were adjusted to 2011 dollars. RESULTS: Alendronate 70 mg once
weekly dominated the “no treatment” and the ibandronate treatments. The rise-
donrate 35 mg to alendronate 70 mg incremental cost-effectiveness ratio (ICER)
demonstrated that for every $469,553 spent one additional hip fracture would be
avoided. These results were consistent throughout the one-way sensitivity analy-
sis, which varied the cost per hip fracture and the efficacy of each medication.
When the incidence of hip fracture was assumed to be 3.57%, risedronate also
dominated the” no treatment” and ibandronate groups. CONCLUSIONS: Alendro-
nate 70mg once weekly was dominate in preventing hip fractures compared to
risedonrate, ibandronate and no treatment. The risedronate to alendronate ICER
demonstrated that the cost to avoid one hip fracture was $469,553 – typically be-
yond most payers’ willingness to pay.
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OBJECTIVES: Rheumatoid arthritis (RA) affects1.3million Americans, accounting
for 9million physician visits and250,000 hospitalizations annually. Drug therapy
is costly but essential. This study evaluates the cost-effectiveness of golimumab, a
recently approved TNF- inhibitor (TNF-I) compared with existing agents (inflix-
imab, etanercept, adalimumab), when given in combination with methotrexate
(MTX) from a third-party payer perspective.METHODS: A Markov model was con-
structed to follow a hypothetical cohort of 10,000 patients with active RA who
received one of the four TNF-I and MTX across patient life-time. The primary ef-
fectiveness outcomes were the American College of Rheumatology (ACR)-20 re-
sponse ratesmapped to health assessment questionnaire-scores to derive quality-
adjusted life-years (QALYs). ACR-20 rates were derived from a systematic review of
efficacy trials. Long-term drug withdrawal rates were derived from observational
studies. Data for drug, administration, monitoring, toxicity and RA-related direct
costs were derived from the literature. Incremental costs (2011 US$) per QALYwere
compared between TNF-Is. One-way and probabilistic sensitivity analysis (PSA)
techniques were employed to examine effects of various assumptions and param-
eter uncertainty. RESULTS: GolimumabMTX generated the highest per-person
QALYs (3.75 QALY), whereas infliximabMTX strategy generated the least QALYs
(3.57). InfliximabMTX resulted in the least direct costs of $317,455 over the pa-
tient’s life-time compared to etanerceptMTX ($324,855), adalimumabMTX
($323,503) and golimumabMTX ($324,159). The base-case incremental cost-effec-
tiveness ratios (ICERs) foretanerceptMTX, adalimuamabMTX, and
golimumabMTXcompared to infliximabMTXwere $69,211, $44,465 and $38,255/
QALY, respectively. GolimumabMTX dominated etanerceptMTX, while the
ICER for golimumabMTX vs adalimumabMTX was $16,729/QALY. In one-way
sensitivity analyses, these results were robust to a range of assumptions except for
dosing of infliximab and long-term withdrawal rates. In the PSA, the probability of
golimumab being cost-effective at the commonly accepted $50,000/QALY thresh-
old was 0.29. CONCLUSIONS: Golimumab appears to be a cost-effective treatment
option for RA compared to existing TNF-Is.
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OBJECTIVES: Nonsteroidal antiinflammatory drugs (NSAIDs) plus a proton pump
inhibitor (PPI) are in widespread use for rheumatic diseases in Algeria, but can
cause peptic ulcers and gastrointestinal bleeding and perforation. The National
Institute for Health and Clinical Excellence (NICE) health economic model for as-
sessing the cost-effectiveness of celecoxib compared to multiple NSAIDSPPI in
the treatment of osteoarthritis has been updated using new adverse event (AE)
risks from the CONDOR trial. In light of this new information, this study aimed to
evaluate the incremental cost-effectiveness ratio (ICER) of celecoxib compared to
different NSAIDS PPI. METHODS: The NICE model was adapted for this study to
update the relative risks of adverse events; using data from the CONDOR trial for
patients above 65yrs. Patients could initiate treatment with celecoxib, NSAIDs (di-
clofenac, naproxen, ibuprofen) plus omeprazole. Conditional probabilities of the
model were obtained from published clinical trials and effectiveness measure was
the Quality-Adjusted life years gained (QALY). The analysis was conducted from
the healthcare payer’s perspective. Resource use and costs were obtained from
official Algerian databases. Probabilistic sensitivity analysis (PSA) was performed
and acceptability curves were constructed. RESULTS: Celecoxib showed on the
six-months period lower expected costs per patient (US$422.84) compared to
naproxenPPI (US$445.79) and ibuprofenPPI (US$775.11). The lowest expected
costs resulted for diclofenacPPI (US$257.10). On the other hand, celecoxib was
associated with higher effectiveness (0.398 QALYs), followed by ibuprofenPPI
(0.393 QALYs) and naproxenPPI (0.392 QALYs). Likewise, celecoxib has an ICER of
US$343.81 per QALY compared to diclofenac which is below 1 GDP per capita for
Algeria (US$7,300). Acceptability curves showed the same results with a mean of
65.5% of certainty. CONCLUSIONS: (DISCUSSION): The results suggest that when
new AE risks are used, celecoxib remains a cost-effective treatment for OA when
compared to diclofenac plus a PPI and cost-saving when compared to
naproxenPPI or ibuprofenPPI.
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OBJECTIVES: Osteoarthritis is a major cause of musculoskeletal pain and inability
to work. Evidence shows that clinical improvement after viscosupplementation
(VS) is able to delaying the average time until total knee arthroplasty (TKA) indica-
tion. This study aimed to conduct cost-effectiveness and budget impact analysis
(BIA) of viscosupplementation with Orthovisc™ (Hyaluronan) versus conservative
treatment in Kellgren & Lawrence(K&L) grades II and III knee osteoarthritis (KOA)
from the Brazilian private health care system perspective. METHODS: A 3-year
time horizon Markov simulation model was developed to project costs and out-
comes associated to KOA progression. Patients could start in ‘Orthovisc™ Treat-
ment’ (conservative treatment  Orthovisc™) or ‘Conservative Treatment’ states
and then transit (6-month cycle duration) in states ‘TKA’, ‘Post-operative’ and
‘Death’ according to transition probabilities extracted from systematic review.
Only direct medical costs were considered and collected from Brazilian private
official databases. Outcome was expressed as ‘avoided TKA procedure’. BIA was
developed for a hypothetical private health insurance cohort of 10,000 patients
over 50 years. Univariate sensitivity analyseswere performed formain parameters.
A 5% annual discount rate was applied for costs and benefits. RESULTS: For a
hypothetical 1000 patient’s cohort in a 3-year time horizon, 34TKAwere performed
in Orthovisc™ group versus 164TKA in conservative treatment group, avoiding 130
TKA procedures. Total costs per group were 17,367,259BRL and 17,494,500BRL for
Orthovisc™ and conservative treatment groups, respectively, with an incremental
cost of -127,241BRL. Sensitivity analysis showed cost-saving results for years 2 and
3. BIA showed savings of 180,401BRL for the private health insurance and 99TKA
avoided in a 3-year time horizon. CONCLUSIONS: Viscosupplementation treat-
ment, based on a Markov simulation model using Orthovisc™ data, in K&L grades
II and III KOA showed to be cost-saving regarding avoided TKA in a 3-year time
horizon over conservative treatment at Brazilian private health care system, lead-
ing to reduction in costs and surgical procedures.
PMS35
THE COST-EFFECTIVENESS OF PEGLOTICASE IN THE TREATMENT OF
REFRACTORY CHRONIC GOUT
Wang BCM1, Garrison L2
1Adjility Health, New York, NY, USA, 2University of Washington Department of Pharmacy,
Seattle, WA, USA
OBJECTIVES: Refractory Chronic Gout (RCG) affects approximately 4% of patients
with gout. It is characterized by failure to achieve normal serum uric acid levels or
adequately control gout signs and symptoms with xanthine oxidase inhibitors at
the maximum medically appropriate dose, or by contraindication to the use of
these drugs. Pegloticase was recently launched in the US for treatment of RCG.
METHODS: We developed a two-part sequential model: 1) the first 6 months rep-
resented as a decision tree; and 2) the remaining years as separate empirical fore-
casts. We modeled the severity of RCG as a combination of flares/year and tophi
status. We used data from two replicate, randomized, double-blind, placebo-con-
trolled trials (C0405 and C0406), which were conducted between June 2006 and
October 2007 in 56 rheumatology practices. The comparator group is placebo. To
model disease progression, we employed a vector autoregression methodology to
approximate Markov Chain transition probabilities. We estimated utility regres-
sions fromNHWSanduse a blended cost of $2600/vial. RESULTS: For a 20-year time
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